Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis.
Conclusions: Baseline factors, including weight and cardiometabolic status, were associated with response to secukinumab. Early onset of response may indicate treatment efficacy later on.
PMID: 31287332 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Cardiology | Dermatology | Diabetes | Enbrel | Endocrinology | Heart | Hypertension | Metabolic Syndrome | Psoriasis | Skin | Smokers | Stelara